Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Manchester United PLC (MANU) vs TransMedics Group Inc (TMDX) Price & Performance

Manchester United PLCTrade
TransMedics Group IncTrade

Price performance (Past 24H)

Key statistics

Manchester United PLC vs TransMedics Group Inc — how do they compare? Manchester United PLC trades at $22.23 (market cap $3.80B), while TransMedics Group Inc trades at $87.08 (market cap $3.10B). The key difference: Manchester United PLC is the larger of the two by market cap, and Manchester United PLC pays a 1.26% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.

MANUTMDX
Market Cap
$3.80B$3.10B
Sector
MediaTechnology
52-Week High
$23.53$150.42
52-Week Low
$15.10$61.99
Enterprise Value
$4.74B$3.49B
Dividend Yield
1.26%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Manchester United PLC

Manchester United (MANU) trades at $22.88, up 5.44% on the day, with a bearish technical signal. The company reported a net loss of $33.02M for 2025, though revenue grew to $666.51M. Recent news highlights the acquisition of land for a new 100,000-seat stadium as a significant long-term de-risking milestone. Cash flow from operations remains positive at $72.70M, but negative profitability metrics and high debt levels persist.

The outlook is mixed; stadium development and Champions League qualification offer growth catalysts, but consistent net losses and weak margins pose fundamental risks. Analyst consensus is neutral with a 60% hold rating. The stock's trajectory hinges on successful execution of cost reductions and capitalizing on new revenue streams from the stadium project.

TransMedics Group Inc

TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.

The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.

Returns comparison

Trailing returns across standard periods

About Manchester United PLC

Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.

Read more on MANU

About TransMedics Group Inc

TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.

Read more on TMDX